Skip to main content
. 2019 Dec 18;199(3):314–325. doi: 10.1111/cei.13404

Figure 3.

Figure 3

Serum levels of neopterin in dermatomyositis patient subgroups stratified by survival status. (a) All patients; (b) patients with rapidly progressive interstitial lung disease (RP‐ILD); (c) patients with cancer‐associated myositis (CAM); (d) patients with anti‐melanoma differentiation‐associated gene (MDA5) antibody‐positive.